Related Experiment Video
Updated: May 6, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
1.0K
Splenic marginal zone lymphoma: disease features and management
1Haematopathology Unit, Hospital Clinic . Barcelona University, Villarroel, 170, 08036 Barcelona, Spain +34 663 109 312 +34 932 275 717 estella.matutes.juan@gmail.com.
Expert Review of Hematology
|October 31, 2013
Summary
Splenic marginal zone lymphoma (SMZL) is a heterogeneous lymphoma. Watchful waiting is recommended for asymptomatic patients, while symptomatic cases may benefit from rituximab-based therapy.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Splenic marginal zone lymphoma (SMZL) is a distinct entity in lymphoid tumor classifications.
- It likely arises from antigen-driven expansion of marginal zone B-cells.
- SMZL exhibits significant clinical and biological heterogeneity.
Purpose of the Study:
- To summarize current guidelines for diagnosing, evaluating, and treating SMZL.
- To outline management strategies based on patient symptoms and available data.
- To identify areas for future research and therapeutic advancements.
Main Methods:
- Review of guidelines from the SMZL Working Group.
- Analysis of retrospective data on treatment efficacy.
- Discussion of diagnostic criteria and workup procedures.
Main Results:
- No standard criteria exist for initiating SMZL treatment.
- A 'watch and wait' approach is advised for asymptomatic patients.
- Rituximab, with or without chemotherapy, appears optimal for symptomatic SMZL.
Conclusions:
- Management of SMZL requires individualized approaches.
- Optimal chemotherapy regimens and the role of splenectomy require further investigation.
- Targeting molecular lesions holds promise for future SMZL therapies.
